Insulet Enhances Omnipod 5 Algorithm, Expands Sensor Compatibility

Event summary

  • Insulet rolled out enhanced Omnipod 5 algorithm in the U.S. following FDA 510(k) clearance in December 2025.
  • New algorithm includes a 100 mg/dL Target Glucose option, expanding personalization for diabetes management.
  • Omnipod 5 now compatible with Abbott’s FreeStyle Libre 3 Plus sensor, increasing user choice.
  • Over-the-air software update to be pushed to existing Omnipod 5 users.

The big picture

Insulet’s algorithm enhancements and sensor compatibility expansion reflect a broader trend in diabetes management toward personalized, automated insulin delivery. The move aligns with industry shifts toward interconnected health ecosystems, potentially strengthening Insulet’s position in the competitive automated insulin delivery market. The integration with Abbott’s sensor also highlights the growing importance of partnerships in medical device innovation.

What we're watching

Algorithm Performance
How the enhanced algorithm will impact time in range (TIR) and user satisfaction.
Market Expansion
The pace at which international rollouts of Libre 3 Plus compatibility will proceed.
Competitive Dynamics
Whether expanded sensor choice will strengthen Omnipod 5’s market position.